

# ASX ANNOUNCEMENT

21 June 2022

## SIX MONTH FOLLOW UP SHOWS 86% IMPROVEMENT IN HAEMODYNAMICS

Anteris is pleased to announce the 6 month follow up of our first cohort of 5 patients. The 6 month follow up is informal (formal follow ups according to the study protocol are 30 days and 1 year). All patients are doing very well and in fact have shown marked improvements since the 3 month follow up.

Key data continues to show exceptional haemodynamics (peak mean gradient have reduced 86% since baseline and 6% since the 3 month follow up).

Importantly 6-minute walk test which is a key marker of patient well-being has improved 46% since baseline and a further 21% improvement between 3 months and 6 months, demonstrating how much more active and fit these patients are able to become. Laminar flow on MRI continues to show significant improvements when compared to existing valves. This aspect of the DurAVR™'s performance is expected to bring significant clinical/patient benefits in the future.

“We continue to see encouraging results in our first group of patients at the 6-month mark. DurAVR™ demonstrates sustained excellent haemodynamics which results in dramatic improvements in patients’ ability to exercise etc. With an additional eight patients having been implanted recently our data and knowledge continues to expand demonstrating that DurAVR™ will hold an important role in the future treatment of aortic stenosis” commented Chris Meduri, MD MPH and Anteris CMO.

“We are thrilled to see our patients doing so well 6 months after receiving DurAVR™. The valve is demonstrating clinically relevant haemodynamics, laminar flow and patient outcomes. With 13 patients now implanted with DurAVR™ we are confident that Anteris will be a significant player in the aortic stenosis market in the years ahead” said Wayne Paterson Anteris CEO.

**ENDS**

**Anteris Technologies Ltd Registered Office:**

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

**Customer Service**

T +61 1300 550 310 | F +61 1300 972 437 | E [info.au@anteristech.com](mailto:info.au@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga



### **About Anteris Technologies Ltd (ASX: AVR)**

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

### **Authorisation and Additional information**

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

#### **For more information:**

Hannah Howlett

WE Communications

E: [WE-AUAnterisTech@we-worldwide.com](mailto:WE-AUAnterisTech@we-worldwide.com)

P: +61 4 5064 8064

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)

LinkedIn: <https://www.linkedin.com/company/anteristech>